Price
No data yet.
Social Signal Score
Analyst Ratings
4 analystsRevenue
$2.51M+8555.17%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Deborah L. Birx
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 61
- Beta
- 1.35
- Country
- US
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- -17.43
Financials
Revenue
$2.51M+8555.2%Net Income
$74.14MEBITDA
$81.37MFree Cash Flow
$-8.68MEPS (diluted)
$-0.27Shares Outstanding (diluted)
62.04M+78007.7%Operating Expenses
$12.82MCash & Debt
$23.95MReturn of Capital
$0.00Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $4.90M | $-173.80M | $-4.80 |
| 2024 | $5.17M | $-18.92M | $-0.52 |
| 2023 | $4.53M | $-69.05M | $-1.91 |
| 2022 | $5.51M | $-36.92M | $-1.08 |
| 2021 | $4.47M | $-23.16M | $-0.96 |
| 2020 | $823.0K | $-22.18M | $-1.35 |
| 2019 | $0.00 | $-19.48M | $-2.43 |
| 2018 | $0.00 | $-12.11M | $-8.90 |
| 2017 | $115.0K | $-12.84M | $-28.14 |
| 2016 | $260.0K | $-18.84M | $-345.80 |
| 2015 | $475.0K | $-516.0K | $-278.60 |
| 2014 | $409.0K | $23.11M | $589.40 |
| 2013 | $325.0K | $-64.58M | $-4479.97 |
| 2012 | $664.0K | $-1.11M | $-161.76 |
Valuation
ARMPhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
160+220.00%Social Signal Score
Mentions (5)
- Newsbenzinga.com·12d ago·Neutral
Armata Pharmaceuticals Stock Slides after Pentagon Funding Fuels Phase 3 Push for Anti-Bacterial Program Armata Pharmaceuticals Inc. (AMEX:ARMP) shares are trading lower on Wednesday as traders digest additional non-dilutive funding tied to its lead bacteriophage program.
View source ↗ - Newsprnewswire.com·13d ago·Positive
… expands total non-dilutive support for the AP-SA02 program to $32.4 million LOS ANGELES, Sept. 23, 2026 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of high-purity and potency, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced that it has received an additional $3.7 million in n…
View source ↗ - Newsprnewswire.com·22d ago·Neutral
…py, Fast Track and QIDP designations, providing strong regulatory validation LOS ANGELES, Sept. 14, 2026 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of high-purity and potency, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced that the U.S. Food and Drug Administration (the "FDA…
View source ↗ - Newsprnewswire.com·33d ago·Positive
…ing of Phage Biology to Support Development of Next-Generation Antibacterials LOS ANGELES, Sept. 3, 2026 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced a paper in the Journal of Molecular Biology, a peer-reviewed jou…
View source ↗ - Newsprnewswire.com·54d ago·Neutral
Armata Pharmaceuticals Announces Financial Results for the Second Quarter 2026 and Provides a Corporate Update LOS ANGELES, Aug. 12, 2026 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced financial results for its secon
View source ↗
Earnings
Wed, Nov 11(in 5 weeks)
Consensus estimate $-0.57 per share
Typical surprise -15.4% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Aug 12$-0.27 vs $-0.45beat
- Wed, May 13$-3.16 vs $-0.38miss
- Wed, Mar 25$-3.42 vs $-0.19miss
- Wed, Nov 12$-0.74 vs $-0.42miss
- Tue, Aug 12$-0.45 vs $-0.39miss
- Wed, May 14$-0.20 vs $-0.38beat
Estimates and results for ARMP via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by ARMP officers and directors.
- Bought
- $85.1m
- Sold
- —
6 trades
0 trades
- Innoviva Strategic Opportunities Llcbought
- Innoviva, Inc.bought
- Innoviva, Inc.bought
- Innoviva, Inc.bought
- Innoviva, Inc.bought
- Innoviva, Inc.bought
92 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in ARMP.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.